reference/14140179

http://rdf.ncbi.nlm.nih.gov/pubchem/reference/14140179

Outgoing Links

Predicate	Object
contentType	Journal Article\|Research Support, N.I.H., Extramural\|Research Support, Non-U.S. Gov't\|Research Support, U.S. Gov't, Non-P.H.S.
endingPage	1089
issn	1875-8908 1387-2877
issueIdentifier	4
pageRange	1079-1089
publicationName	Journal of Alzheimer's disease : JAD
startingPage	1079
hasFundingAgency	http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_916de93fe8f49855f42e16db43537393
isSupportedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_b29abe85f886f68f5bbad81ccdaf223e
bibliographicCitation	Burnham SC, Raghavan N, Wilson W, Baker D, Ropacki MT, Novak G, Ames D, Ellis K, Martins RN, Maruff P, Masters CL, Romano G, Rowe CC, Savage G, Macaulay SL, Narayan VA; Alzheimer’s Disease Neuroimaging Initiative; AIBL Research Group. Novel Statistically-Derived Composite Measures for Assessing the Efficacy of Disease-Modifying Therapies in Prodromal Alzheimer's Disease Trials: An AIBL Study. J Alzheimers Dis. 2015;46(4):1079–89. doi: 10.3233/jad-143015. PMID: 26402634.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_b603a03417527447f83623d097fd8013 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_60c70154ce5c3729b069b6fbbf002151 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_be75bc43bfb92c5b4244a5cb07c51384 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_2648a0265998e0ab09b354f7c65ef941 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_d7a880f17516628a0db6f804695de5ed http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_c517bb8c01962486ac1ee2f3518908ca http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0002-6947-9537 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_5d7ddae565c8d7c179c4f96a4f19ac4d http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_27fb7528cc41fd829230be14163cbe41 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_74fb3646d82116d505793ad759ee747c http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_5c773f57355ec2b46ad04f5225a982f0 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_f14a79e81196e2077a717bb5686d432d http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_1bb54545e9b960bc0aeb11b0e4338d64 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_66f0bedb210b9f617ade9494e58fca0d http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_63d952d821fdec82354aca51823909c8 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_bcf4adc5eeb8a99e462ac21f81264273 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_c0b404ea3ca7a75243bdaef169eac6f3
date	2015-06-26-04:00^^<http://www.w3.org/2001/XMLSchema#date>
identifier	https://doi.org/10.3233/jad-143015 https://pubmed.ncbi.nlm.nih.gov/26402634
isPartOf	https://portal.issn.org/resource/ISSN/1387-2877 http://rdf.ncbi.nlm.nih.gov/pubchem/journal/21942 https://portal.issn.org/resource/ISSN/1875-8908
language	English
source	https://pubmed.ncbi.nlm.nih.gov/ https://www.crossref.org/
title	Novel Statistically-Derived Composite Measures for Assessing the Efficacy of Disease-Modifying Therapies in Prodromal Alzheimer’s Disease Trials: An AIBL Study
discusses	http://id.nlm.nih.gov/mesh/M0021333 http://id.nlm.nih.gov/mesh/M0451542 http://id.nlm.nih.gov/mesh/M0001601 http://id.nlm.nih.gov/mesh/M0001215 http://id.nlm.nih.gov/mesh/M0023752
hasPrimarySubjectTerm	http://id.nlm.nih.gov/mesh/D000544Q000523 http://id.nlm.nih.gov/mesh/D000544Q000235 http://id.nlm.nih.gov/mesh/D008019 http://id.nlm.nih.gov/mesh/D000544Q000628 http://id.nlm.nih.gov/mesh/D062706 http://id.nlm.nih.gov/mesh/D059906Q000379 http://id.nlm.nih.gov/mesh/D000544Q000175
hasSubjectTerm	http://id.nlm.nih.gov/mesh/D008137 http://id.nlm.nih.gov/mesh/D000368 http://id.nlm.nih.gov/mesh/D013844Q000378 http://id.nlm.nih.gov/mesh/D008609 http://id.nlm.nih.gov/mesh/D015415Q000378 http://id.nlm.nih.gov/mesh/D018450 http://id.nlm.nih.gov/mesh/D000814Q000378 http://id.nlm.nih.gov/mesh/D001057Q000235 http://id.nlm.nih.gov/mesh/D015203 http://id.nlm.nih.gov/mesh/D008297 http://id.nlm.nih.gov/mesh/D009483 http://id.nlm.nih.gov/mesh/D001315 http://id.nlm.nih.gov/mesh/D005260 http://id.nlm.nih.gov/mesh/D006801

Total number of triples: 64.